NEOADJUVANT MELANOMA

Clinical trials for NEOADJUVANT MELANOMA explained in plain language.

Never miss a new study

Get alerted when new NEOADJUVANT MELANOMA trials appear

Sign up with your email to follow new studies for NEOADJUVANT MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Terminated 1

New IL-2 drug aims to supercharge immune attack on Hard-to-Treat cancers

Disease control Ongoing

This study tests an experimental drug called TransCon IL-2 β/γ, which is designed to boost the immune system's ability to fight advanced solid tumors. About 320 adults with cancers like ovarian, melanoma, lung, or cervical cancer will receive the drug alone or combined with other…

Matched conditions: NEOADJUVANT MELANOMA

Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control

Last updated May 17, 2026 06:20 UTC

NEOADJUVANT MELANOMA

Get alerted when new NEOADJUVANT MELANOMA trials appear

New IL-2 drug aims to supercharge immune attack on Hard-to-Treat cancers